Toll Brothers Announces New Luxury Home Community Coming Soon to Corona, California

Rhea-AI Summary

Toll Brothers (NYSE:TOL) announced Enclave by Toll Brothers, a 35‑home luxury single‑family community coming to Corona, California, with site work underway at Santana Way and Garretson Ave and sales anticipated to begin in early fall 2026. Homes will feature one‑ and two‑story plans with up to 5 bedrooms, 4.5–5.5 baths, 2–4 car garages, and personalization via the Toll Brothers Design Studio. Community amenities include a park with green space, lounge seating and a BBQ area. The location offers access to hiking, shopping, dining and schools in the Corona‑Norco Unified School District. Contact (866) 232‑1631 or TollBrothers.com/CA for the interest list.

News Market Reaction

+0.08%

1 alert

+0.08% News Effect

On the day this news was published, RNA gained 0.08%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Clinical programs: 3 programs Trial phase: Phase 3 Awareness month: September +5 more

8 metrics

Clinical programs 3 programs DM1, FSHD, DMD44 muscular dystrophy programs

Trial phase Phase 3 Global HARBOR study for DM1

Awareness month September National Muscular Dystrophy Awareness Month activities

MDF Gala date September 14, 2024 2024 MDF Gala in Los Angeles

World Duchenne Day September 7 Jett Foundation Stronger than Duchenne events

Global Genes Week September 25–28 2024 Global Genes Week in RARE, Kansas City

FSHD Walk & Roll September 21 FSHD Society Walk & Roll in San Diego and other locations

Family Forum date September 21 Defeat Duchenne Canada 2024 Family Forum in Ontario

Market Reality Check

Price: $72.89 Vol: Volume 1,757,846 is about...

normal vol

$72.89 Last Close

Volume Volume 1,757,846 is about 1.44x the 20-day average. normal

Technical Price 144.92 is trading above the 200-day MA at 124.23 and 3.26% below the 52-week high.

Peers on Argus

TOL fell 2.61% while peers were mixed: NVR -0.49%, PHM -1.34%, DHI +0.47%, LEN +...

TOL fell 2.61% while peers were mixed: NVR -0.49%, PHM -1.34%, DHI +0.47%, LEN +0.53%, TMHC -2.31%, indicating a stock-specific move rather than a uniform sector trend.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Model homes opening	Positive	+1.1%	Grand opening of two luxury model homes at Woodinville Square.
Jan 12	Model homes opening	Positive	+1.1%	Opening of Brasada and Alderbrook models at Camas Meadows Crossing.
Jan 09	New home designs	Positive	+7.2%	Launch of two new single-level ranch home designs in Georgia community.
Jan 07	Leadership succession	Neutral	-0.9%	CEO transition to Executive Chairman and promotion of new CEO.
Jan 07	Community announcement	Positive	-0.9%	Announcement of Vintage Grove luxury community in North Carolina.

Pattern Detected

Operational expansion announcements have often coincided with positive price moves, though there has been at least one negative reaction to similar community-launch news.

Recent Company History

Over recent months, TOL has frequently announced new communities and model-home openings in markets like Washington, Georgia, and North Carolina. Several of these updates, such as new ranch designs at Aurora Ridge at Great Sky in Canton, Georgia, saw a +7.24% reaction, while two Washington announcements on Jan 12, 2026 coincided with +1.08% moves. Leadership succession news on Jan 7, 2026 drew a modest negative reaction, highlighting mixed responses to non-operational updates.

Market Pulse Summary

This announcement adds to a series of new luxury community and model-home updates for Toll Brothers,...

Analysis

This announcement adds to a series of new luxury community and model-home updates for Toll Brothers, reinforcing its focus on higher-end residential projects. Recent history shows that some similar operational announcements coincided with positive moves, including a +7.24% reaction to new ranch designs, while others saw modest declines. Investors tracking this news may watch how it affects geographic mix, pricing, and follow-on disclosures in upcoming filings or updates.

Key Terms

duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, antibody oligonucleotide conjugates, +2 more

6 terms

duchenne muscular dystrophy medical

"Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44)"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

myotonic dystrophy type 1 medical

"del-desiran™ for myotonic dystrophy type 1 (DM1)"

A genetic, progressive disorder that causes muscle stiffness, weakness and a range of problems in other body systems (such as breathing, heart rhythm, vision and cognition); symptoms can vary widely and often worsen over time. For investors, it matters because its chronic, multisystem nature shapes the size of the potential patient population, the complexity and cost of clinical trials, regulatory requirements, and long-term demand for any effective treatments — think of it as a condition that requires multiple pieces to be fixed, not just a single part.

facioscapulohumeral muscular dystrophy medical

"del-brax™ for facioscapulohumeral muscular dystrophy (FSHD)"

A genetic progressive muscle disorder that slowly weakens the face, shoulder blades and upper arms, often making everyday actions like smiling, lifting objects or raising the arms harder over time. Investors care because it represents a clear unmet medical need: treatments or tests that slow progression, restore function, or improve diagnosis can command significant demand and regulatory attention, similar to developing a new fix for a widespread, uncontrolled mechanical fault in a critical system.

antibody oligonucleotide conjugates medical

"RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™)"

A therapy made by chemically attaching a short strand of genetic material (an oligonucleotide) to an antibody so the antibody can carry that genetic payload directly to specific cells. Think of the antibody as a guided delivery vehicle and the oligonucleotide as a small instruction manual that can turn genes on or off. Investors care because this approach aims to increase effectiveness and reduce side effects, but it also raises development complexity, regulatory scrutiny, and potential for high reward if clinically successful.

phase 3 medical

"advanced our DM1 program into a global Phase 3 study"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

clinical trials medical

"learn more about the latest advancements in research, clinical trials, and advocacy"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

AI-generated analysis. Not financial advice.

CORONA, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Enclave by Toll Brothers, is coming soon to Corona, California. This exclusive Toll Brothers neighborhood in Southern California will include just 35 single-family home sites and an array of luxury amenities. Site work is underway at Santana Way and Garretson Ave in Corona, and the community is anticipated to open for sale in early fall 2026.

Enclave by Toll Brothers is a boutique community of luxury homes that will provide residents with an idyllic blend of serenity and convenience. Featuring expansive home sites, this community will offer spacious, modern single-family home designs with one- and two-story open floor plans, 5 bedrooms, 4.5 to 5.5 baths, 2- to 4-car garages, and an array of versatile personalization options.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

“We are excited to bring our exceptional home designs to this unique setting and location in Corona later this year,” said Brad Hare, Division President of Toll Brothers in Southern California. “Enclave by Toll Brothers will be an intimate community of limited home sites, offering a unique opportunity for luxury living in this highly desirable area.”

Enclave by Toll Brothers will include a park with green space and lounge seating as well as a community BBQ area. Residents will experience luxury living in a convenient location close to nearby hiking trails and parks, upscale shopping and dining, and excellent schools. Children will be served by top-rated public schools in the Corona-Norco Unified School District, including the highly desirable Santiago High School, as well as private schools.

Well-located in the Inland Empire in northwest Riverside County, the city of Corona borders Orange County to the west and is approximately 45 miles southeast of Los Angeles, providing additional opportunities for residents to explore everything that Southern California has to offer.

For more information and to join the interest list for Enclave by Toll Brothers, call (866) 232-1631 or visit TollBrothers.com/CA.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/93c27910-bf40-4471-a627-4cc2887fdd8d
https://www.globenewswire.com/NewsRoom/AttachmentNg/879938e1-eecf-4494-a7da-ce0a40ee05f8
https://www.globenewswire.com/NewsRoom/AttachmentNg/78f4e5e9-3efa-4744-958e-e326a000b451

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

FAQ

When will Toll Brothers (TOL) begin selling homes at Enclave by Toll Brothers in Corona, CA?

Sales are anticipated to begin in early fall 2026.

What home sizes and floor plans will Toll Brothers offer at Enclave (TOL) in Corona?

Enclave will offer one‑ and two‑story single‑family homes with up to 5 bedrooms, 4.5–5.5 baths, and 2–4 car garages.

How many homes will be in the Enclave by Toll Brothers community in Corona (TOL)?

The community will include 35 single‑family home sites.

What amenities will residents find at Enclave by Toll Brothers in Corona (TOL)?

Planned amenities include a park with green space, lounge seating and a community BBQ area.

How can prospective buyers join the interest list for Enclave by Toll Brothers (TOL)?

Call (866) 232‑1631 or visit TollBrothers.com/CA to join the interest list.